February 16, 2021 : Issue #1107

DISASTERS AVERTED — Near Miss Case Studies

Excessive Bleeding after Injection Raises Suspicions

TOP STORIES — Diabetes News and Research

Common Diabetes Medication as Treatment for Parkinson’s Disease

Brain Damage Associated with High Blood Glucose

Left Ventricular Mass Reduction and Empagliflozin

MOST POPULAR ARTICLES OF THE MONTH

#1 Critical Changes to the 2021 ADA Standards of Care

#2 Fasting Glucose Variation Predicts Microvascular Risk

#3 Using SGLT-2 Inhibitors to Significantly Reduce AFib

The number of people who are diagnosed with Parkinson’s disease increases every year. 10 years ago there were less than 300,000 diagnosed cases in the US, and now the number is just over 1 million, with about 60,000 -70,000 new cases diagnosed each year. Currently about 1% of the over 60 population is diagnosed, and in patients over 85 that number jumps to 5%. We have medications to treat the symptoms but slowing the progression of the disease is not something we do very well. Now a retrospective review of patients taking two different diabetes drugs shows a real and measurable decrease in onset and severity of the disease.

Arjay Mendoza, PharmD Candidate, University of Colorado School of Pharmacy, in this week’s Laterpay article brings us information on a new study going on in the United Kingdom, that looks at the use of a GLP-1 agonist in non-diabetes patients to reduce the onset of Parkinson’s.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

A man 79 years of age was referred to me to start insulin. As a diabetes educator, I don’t always have a full history and comprehensive labs given to me from the PCP. I met the patient and his family who told me his history, medications, lifestyle, etc….

Findings show Parkinson’s disease risk is reduced in patients with type 2 diabetes mellitus (T2DM) after treatment with exenatide.

Researchers continue to uncover the many ways uncontrolled hyperglycemia can damage the body.

Empagliflozin significantly lowered LVMi, systolic blood pressure, and diastolic blood pressure in patients with CAD and type 2 diabetes.